Wave Life Sciences Ltd.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd.

Overview
Date Founded

2012

Headquarters

7 Straits View,Marina One East Tower,No. 12-00,Singapore, Central Singapore 018936

Type of Company

Public

Employees (Worldwide)

301

Industries

Biotechnology

Company Description

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Contact Data
Trying to get in touch with decision makers at Wave Life Sciences Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President, Chief Executive Officer & Director

General Counsel

Chief Technology Officer

Chief Medical Officer, Head of Therapeutics Discovery & Development

Senior Vice President, Corporate Development & Head of Emerging Areas

Senior Vice President, Finance & Operations

Senior Vice President, Corporate Affairs & Patient Advocacy

Senior Vice President, Therapeutics Discovery

Executive Officer

Investor Relations Contact

Paths to Wave Life Sciences Ltd.
Potential Connections via
Relationship Science
You
Wave Life Sciences Ltd.
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

NCM utilizes a long-term fundamental value investing methodology with a primary focus on small to mid-sized US companies. They practice research intensive, fundamental security selection and base their investment decisions on internally generated research and research obtained from outside sources. The firm focuses on intrinsic value by identifying securities which are mispriced relative to the real economic value they represent and on the expected timing for the mispricing to be corrected by market forces.

Details Hidden

Ghost Tree Capital seeks to generate absolute returns in the funds that aim to be uncorrelated to broader market conditions by utilizing a long/short equity strategy principally focused on the healthcare industry. By leveraging the medical and financial experience of the Principal and other investment personnel, the firm expects to pursue investments primarily in the areas of biotechnology, pharmaceuticals, medical devices and supplies and healthcare services. However, they generally have broad and flexible investment authority with respect to the funds. Ghost Tree Capital’s research process is focus on forming differentiated views and unique insights into critical value drivers that impact individual company, competitive markets, therapeutic categories and the broader healthcare industry, in order to attempt to identify compelling investments for the funds.

Recent Transactions
Details Hidden

Wave Life Sciences Ltd. issued USD Common Stock

Details Hidden

Wave Life Sciences Ltd. issued USD Ordinary Shares

Details Hidden

Wave Life Sciences Ltd. raised money in a private placement transaction

Transaction Advisors
Underwriter

Advised onWave Life Sciences Ltd. issued USD Common Stock

Escrow Agent

Advised onWave Life Sciences Ltd. issued USD Common Stock

Underwriter

Advised onWave Life Sciences Ltd. issued USD Common Stock

Professional

Advised onWave Life Sciences Ltd. issued USD Common Stock

Managing Director, BioPharma

Advised onWave Life Sciences Ltd. issued USD Common Stock

Managing Director

Advised onWave Life Sciences Ltd. issued USD Common Stock

Clients

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Key Stats and Financials As of 2019
Market Capitalization
$293M
Total Enterprise Value
$165M
Earnings Per Share
$-5.72
Revenue
$16M
TEVNet Income
-0.85x
Enterprise Value / Sales
10.3x
Debt TEV
0.2x
EBITDAMargin
-1,245.8%
Total Equity
$71.6M
EBITDA
$-199M
Total Debt
$32.5M
Net Profit
$-194M
Three Year Compounded Annual Growth Rate Of Revenue
119.91%
Investors
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Cormorant invests in companies primarily located in North America. The firm targets companies in sectors such as life-science and biotech. It provides financing for early stage capital requirements.

Suppliers
Max Planck Society Publishing | Munich, Germany

Max Planck Gesellschaft zur Förderung der Wissenschaften eV (MPG) is an independent foundation headquartered in Munich and was founded in 1948. MPG provides investment advisory services to foundations.

University of Tokyo Tokyo, Japan

The University of Tokyo was established in 1877 as the first national university in Japan. As a leading research university, UTokyo offers courses in essentially all academic disciplines at both undergraduate and graduate levels and conducts research across the full spectrum of academic activity. The University aims to provide its students with a rich and varied academic environment that ensures opportunities for both intellectual development and the acquisition of professional knowledge and skills. To learn more about the University of Tokyo, please visit the pages below.

Competitors
Alnylam Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Biogen, Inc. Biotechnology - Canyon Country, CA

Biogen has some of the world’s best neurologists and neuroscientists. They engage with physicians and scientific leaders around the world with the aim to further medical research. Their focus on neuroscience, their deep scientific expertise and courage to take risks makes them leaders in the research and development of medicines to transform neuroscience to benefit society. Their technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing their high-quality medicines to market faster. They respect the contributions of health care providers caring for people living with neurological diseases. They honor the important role of caregivers, families and friends who care about them.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Wave Life Sciences Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Wave Life Sciences Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Wave Life Sciences Ltd..